Press coverage about NeuroMetrix (NASDAQ:NURO) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeuroMetrix earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 46.3819263255736 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

NURO has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of NeuroMetrix from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Wednesday, July 5th. HC Wainwright set a $16.00 price objective on shares of NeuroMetrix and gave the company a “buy” rating in a research report on Thursday, June 15th.

Shares of NeuroMetrix (NASDAQ NURO) traded down 2.08% on Friday, reaching $1.88. 19,590 shares of the company’s stock traded hands. The firm’s market cap is $4.00 million. NeuroMetrix has a one year low of $1.66 and a one year high of $12.80. The company’s 50-day moving average price is $2.01 and its 200 day moving average price is $1.99.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Thursday, July 20th. The medical device company reported ($2.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.83) by $0.34. NeuroMetrix had a negative net margin of 83.92% and a negative return on equity of 209.56%. The firm had revenue of $4.31 million during the quarter, compared to the consensus estimate of $4.40 million. On average, equities analysts forecast that NeuroMetrix will post ($11.20) EPS for the current fiscal year.

WARNING: “NeuroMetrix (NURO) Getting Somewhat Positive Press Coverage, Report Shows” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at

About NeuroMetrix

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for NeuroMetrix (NASDAQ:NURO)

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.